Clario’s Precision Motion Opal Credited with Oxford Parkinson’s Discovery
Findings offer promising implications for neuroscience clinical trials and future treatments, company says.
Clario, a healthcare research technology company, revealed in a company press release that researchers at Oxford University have successfully developed a new understanding of motor symptom progression in Parkinson's Disease through the use of its Precision Motion Opal technology. Reportedly, a study that leveraged the company’s wearable sensors and machine learning enabled researchers with the ability to track the motor symptom progression in individuals with Parkinson's Disease (PD) better than the conventionally used clinical rating scales. Additionally, results found that the device discovered disease progression in a significantly shorter timeframe than the traditional method.
"We are honored to support Professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field," said Kristen Sowalsky, PhD, DC, VP of Medical & Scientific Affairs, Clario. "This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson's Disease progression more accurately and assess the efficacy of early therapeutic intervention. The potential impact of these findings for neuroscience clinical trials is outstanding."
Reference: Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease. PR Newswire. October 27, 2023. Accessed October 31, 2023. https://www.prnewswire.com/news-releases/clarios-precision-motion-opal-technology-powers-university-of-oxford-breakthrough-in-parkinsons-disease-301969111.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
